|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
German Parkinson Study Group (GPS) Competence Network on Parkinson`s disease |
|---|---|
| Information provided by: | German Parkinson Study Group (GPS) |
| ClinicalTrials.gov Identifier: | NCT00196898 |
Purpose
Fibrotic valvular heart diseases are known as rare complications of long-time therapy of Parkinson's disease with ergot-derivatives including some ergot-dopamine agonists. The aim of this study is to assess the incidence of valvular heart disease, which may be an ergot-drug agonists side-effect or an overall complication of all dopamine agonists. Incidence, prevalence and addiction of dose or intake duration are not known so far. The reversibility of the changes is unknown too. To answer these questions the present study is designed as a cross sectional study followed by a 2 year follow-up prospective cohort study.
| Condition |
|---|
|
Heart Valve Diseases Parkinson's Disease |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | A National, Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson´s Disease Treated With Dopamine Agonists |
| Estimated Enrollment: | 100 |
| Study Start Date: | March 2005 |
| Estimated Study Completion Date: | April 2007 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Karla Eggert, Dr. | +49 (0)6421 2865443 | eggert@med.uni-marburg.de |
| Contact: Wolfgang M. Oertel, Prof. Dr. | +49 (0) 6421 866278 | oertelw@med.uni-marburg.de |
| Germany, Hessen | |
| Universitätsklinikum Marburg und Gießen, Neurologische Klinik | Recruiting |
| Marburg, Hessen, Germany, 35033 | |
| Contact: Wolfgang H. Oertel, Prof. Dr. + 49 6421- 28 66278 oertelw@med.uni-marburg.de | |
| Contact: Karla M. Eggert, Dr. + 49 6421- 28 65443 eggert@med.uni-marburg | |
| Principal Investigator: Wolfgang H. Oertel, Prof. Dr. | |
| Principal Investigator: Karla M Eggert, Dr. | |
| Study Chair: | Wolfgang Oertel, Prof. Dr. | Universitätsklinikum Marburg und Gießen |
More Information
| Responsible Party: | Competence Network on Parkinson´s disease ( Competence Network on Parkinson´s disease, Dr. Karla Eggert ) |
| Study ID Numbers: | 1.0 / 03.02.05, Grant 01 GI 0201/01 GI 0401 |
| Study First Received: | September 12, 2005 |
| Last Updated: | March 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00196898 History of Changes |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
Parkinson´s disease fibrotic valvular heart fibrosis ergot dopamine agonists non-ergot dopamine agonists |
|
Neurotransmitter Agents Heart Diseases Ganglion Cysts Fibrosis Basal Ganglia Diseases Central Nervous System Diseases Cardiovascular Agents Brain Diseases Neurodegenerative Diseases |
Dopamine Agonists Heart Valve Diseases Dopamine Parkinson Disease Movement Disorders Dopamine Agents Peripheral Nervous System Agents Parkinsonian Disorders |
|
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Basal Ganglia Diseases Physiological Effects of Drugs Neurodegenerative Diseases Brain Diseases Dopamine Agonists Dopamine Movement Disorders Therapeutic Uses Cardiovascular Diseases Heart Diseases |
Sympathomimetics Nervous System Diseases Central Nervous System Diseases Cardiovascular Agents Protective Agents Pharmacologic Actions Heart Valve Diseases Parkinson Disease Autonomic Agents Dopamine Agents Parkinsonian Disorders Peripheral Nervous System Agents |
